Dr Giuseppe Bardi graduated at University of Bologna (Italy) in 1998 in Biological Sciences and received the PhD at The Theodor Kocher Institute in Bern (CH) in Cellular and Molecular Immunology in 2001 with a thesis on Chemokine Receptor Signal Transduction. He worked as postdoc fellow on lymphocyte signaling at The Babraham Institute (Cambridge, UK) and on chemokines/opioids cross-talk signaling in leukocytes at the FELS Institute for Cancer Research and Molecular Biology, Temple University (Philadelphia, PA, USA). From January 2005 he focused on the same topic on neurons as Research Associate in the Dep. of Pharmacology and Physiology at Drexel University (USA). In 2006 he moved back to Italy at Neuroscience Institute CNR (Pisa, Italy) and as Contract Professor at the Faculty of Pharmacy, University of Pisa (Italy). Here, he applied his cellular immunology experience to nanomaterial-induced toxicity and immune responses.
Since February 2011 Dr Bardi is a Scientist of the Istituto Italiano di Tecnologia (Genova, Italy), whose research is focused on nanomaterials’ interactions with immune cells. He aims at the development of by tailored nanoparticles to behave as vaccine adjuvants with novel properties.
He is also a member of the Editorial Board of “Vaccines” (MDPI) and Topic Editor for “Nanomaterials” (MDPI). He serves as reviewer for several journals as well as for the Polish “National Science Centre” founding agency (Narodowe Centrum Nauki – NCN, Poland).